Artwork

Content provided by BioTech Nation Team and Moira Gunn. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BioTech Nation Team and Moira Gunn or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

No More Transfusions!!! Dr. John Scarlett, President and CEO of Geron Corporation

16:10
 
Share
 

Manage episode 419651458 series 3360496
Content provided by BioTech Nation Team and Moira Gunn. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BioTech Nation Team and Moira Gunn or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Dr. John Scarlett, President and CEO of Geron Corporation talks about their drug Imetelstat for myelodysplastic syndrome (MDS). MDS patients often require frequent blood transfusions, impacting their quality of life. Imetelstat, a telomerase inhibitor, aims to reduce transfusion dependence by targeting cancer cells in the bone marrow. Phase three trials showed promising results, with 40% of patients experiencing at least an 8-week transfusion-free interval.

  continue reading

90 episodes

Artwork
iconShare
 
Manage episode 419651458 series 3360496
Content provided by BioTech Nation Team and Moira Gunn. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BioTech Nation Team and Moira Gunn or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Dr. John Scarlett, President and CEO of Geron Corporation talks about their drug Imetelstat for myelodysplastic syndrome (MDS). MDS patients often require frequent blood transfusions, impacting their quality of life. Imetelstat, a telomerase inhibitor, aims to reduce transfusion dependence by targeting cancer cells in the bone marrow. Phase three trials showed promising results, with 40% of patients experiencing at least an 8-week transfusion-free interval.

  continue reading

90 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide